[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Assistance Publique Hopitaux De Marseille\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":615},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,113,0,25,[9,46,69,100,126,158,182,210,239,263,282,305,324,352,379,402,421,441,464,483,504,530,551,570,594],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100623645","biomarkers-of-response-to-seeg-thermocoagulation-100623645",false,"NCT07399327","Biomarkers of Response to SEEG Thermocoagulation","Biomarkers of Response to SEEG Thermocoagulation in Patients With Refractory Focal Epilepsy","THALPO","Inclusion Criteria:\n\n* Patient, parents or legal representative who have given their written informed consent,\n* Adult or pediatric patient ≥ 12 years old suffering from drug-resistant focal epilepsy,\n* Standardized pre-surgical assessment including medical history, scalp video-EEG and 3T MRI,\n* Patients in whom a SEEG exploration for pre-surgical evaluation has been indicated,\n* Patient able to understand, speak and write in French,\n* Patient able to follow study's procedure,\n* Patient beneficiary or affiliated to a health insurance plan.\n\nExclusion Criteria:\n\n* Epilepsy surgery performed without the requirement of SEEG,\n* Contraindication to 3T or 7T brain MRI (patient with a cardiac pacemaker, metallic foreign bodies, non-removable implanted electronic medical devices, claustrophobia, inability to remain in supine position, patient havingwith Vagus Nerve Stimulation (VNS) or Deep Brain Sstimulation (DBS), intrauterine devices or tattoos in the imaging area less than 6 weeks old at the time of the 3T\u002F7T brain MRI),\n* Contraindication to gadolinium-based MRI contrast agent (history of allergic or anaphylactic reaction to gadolinium, hypersensitivity to gadoteric acid, meglumine, or any drug containing gadolinium, severe renal failure (glomerular filtration rate, GFR, below 30 ml\u002Fmin\u002F1.73 m2), patients on dialysis or with a history of kidney disease, such as renal transplantation, a single kidney, or renal malignancy),\n* Person protected by articles L1121-5, L1121-6 and L1121-8 of the Public Health Code (pregnant or breastfeeding woman, deprived of liberty by judicial decision, situations of social fragility, adults unable or unable to express their consent),\n* Patient in exclusion period of another study.","ALL","12 Years",{"count":21,"type":22},45,"ESTIMATED","INTERVENTIONAL",[25],"NA","Drug-resistant focal epilepsy is a severe neurological disease that affects one-third of patients with epilepsy. Surgery is the only potentially curative treatment. Intracerebral exploration by stereo electroencephalography (SEEG) is an important step in the surgical pathway. It aims to establish the precise mapping of the epileptogenic network (EZN), including all the brain regions that generate seizures. At the end of SEEG, SEEG-guided radiofrequency thermocoagulation (SEEG RFTC) represents a therapeutic option that may be efficient as a palliative treatment in patients ineligible for resective surgery, or may lead, in some cases, to a definitive effect, avoiding open surgery. The safety and effectiveness of this approach have been established. However, the odds of remaining seizure-free after one year vary greatly between studies, ranging from 4% to 71%. This disparity in therapeutic responses could be linked to the absence of objective criteria for the selection of targets, but also to the existence of mechanisms of action outside of the direct lesional effect. A decrease in SEEG markers of epileptogenicity may predict thermocoagulation efficiency. However, no data are available regarding changes in alteration of the blood-brain barrier (BBB) connectivity, inflammation, or associated molecular changes and their relationship to prognosis.\n\nThis study aims to elucidate the mechanisms underlying the clinical effect of SEEG RFTC by studying the changes in electrophysiological (SEEG), structural (ultra-high field MRI), and biological (blood biomarkers of neuro-glio-vascular damage and inflammation, molecular adaptations) markers. They will be correlated with clinical outcome in a prospective cohort of patients with drug-resistant focal epilepsy. As advantages for clinical care, this study will allow selection of RFTC targets based on scientifically validated criteria, and elaboration of predictive scores for therapeutic response in each patient.\n\nThe primary objective is to study the predictive factors of response to SEEG RFTC, by correlating changes in BBB permeability with clinical response 3 months after RFTC, in a prospective cohort of patients with drug-resistant focal epilepsy.",[28],"Drug Resistant Epilepsy",[30,31,32],"RFTC","Drug resistant epilepsy","SEEG","RECRUITING","2026-06-23",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":37},"2026-06-19",{"date":41,"type":22},"2029-06-30",{"name":43,"class":44},"Assistance Publique Hopitaux De Marseille","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100638889","phase-1-tolerance-of-local-administration-of-cryopreserved-autologous-stromal-vascular-fraction-combined-with-micrograft-for-the-treatment-of-refractory-ano-perineal-fistulas-in-crohns-disease-100638889","NCT07629245","Tolerance of Local Administration of Cryopreserved Autologous Stromal Vascular Fraction Combined With Micrograft for the Treatment of Refractory Ano-perineal Fistulas in Crohn's Disease","ADICROHN3","Inclusion Criteria:\n\n* (1) Signing of a consent form.\n* (2) Patients with Crohn's disease diagnosed at least 6 months prior, in accordance with clinical, endoscopic, histological, and\u002For radiological criteria.\n* (3) Patients previously enrolled in or treated as part of the ADICROHN 2 study.\n* (4) Non-active or mildly active luminal Crohn's disease, defined by a CDAI score ≤ 220.\n* (5) Patients who failed to respond to the ADICROHN-2 protocol, defined by the persistence of anoperineal fistula(s) at the end of the ADICROHN-2 study and their persistence at the time of enrollment.\n* (6) Patients who achieved success (combined remission) at the end of the ADICROHN-2 study but who have a recurrence of anoperineal fistula(s) at the time of enrollment.\n* (7) Sufficient quantity of cryopreserved cells to allow for the innovative treatment, based on the number of fistulas to be treated.\n* (8) Patients over 18 years of age.\n* (9) Good general health based on medical history and clinical examination.\n* (10) Women of childbearing age must have a negative pregnancy test (serum or urine; detection threshold: 25 mIU hCG\u002Fml). Patients of both sexes must use a reliable method of contraception.\n* (11) Enrollment in a social security program.\n\nExclusion Criteria:\n\n* (1) Active, primarily luminal Crohn's disease requiring immediate treatment.\n* (2) Patients who experienced intolerance to the advanced therapy medicinal product during the ADICROHN-2 study.\n* (3) Presence of an abscess or collections \\> 2 cm at the time of enrollment, unless this issue is resolved during the fistula preparation period.\n* (4) Rectal and\u002For anal stenosis and\u002For active proctitis resulting in a limitation of the surgical procedure.\n* (5) Patients currently receiving corticosteroids or who have received them within the four weeks prior to the injection of the investigational product.\n* (6) Malignant tumors or a history of malignant tumors within the past 5 years.\n* (7) Congenital or acquired immunodeficiency.\n* (8) Contraindications to local anesthetics and gadolinium (MRI contrast agent).\n* (9) Contraindications to MRI: metallic foreign bodies (ferromagnetic material) and metallic implants (pacemakers, heart valves, vascular clips, surgical clips or staples, cochlear implants, any implanted electronic medical device or material \\[e.g., insulin pump\\], orthopedic medical prostheses.\n* (10) Treatment with darvadstrocel administered \\\u003C 6 months prior to enrollment)\n* (11) Contraindications to general anesthesia.\n* (12) BMI \\\u003C 18 kg\u002Fm² to ensure an adequate amount of abdominal adipose tissue or other subcutaneous adipose tissue accessible via manual liposuction.\n* (13) Coagulation disorders that contraindicate surgery.\n* (14) Known hypersensitivity to human albumin.\n* (15) Participation in another clinical trial (excluding observational studies).\n* (16) Persons protected under Articles L1121-5, L1121-6, and L1121-8 of the Public Health Code (pregnant or breastfeeding women, persons deprived of liberty by judicial decision, persons in situations of social vulnerability, adults who are legally incapacitated or unable to give informed consent).","18 Years",{"count":7,"type":22},[56,57],"PHASE1","PHASE2","The ADICROHN-3 study is a prospective, multicenter, open-label cohort study.\n\nIts design is supported by the following elements:\n\n* The results of the ADICROHN pilot study (EudraCT No. 2013-002602-31) and our 3-year study, which demonstrate an excellent safety profile with a promising efficacy signal.\n* Data from the literature confirming that cryopreservation of FVS does not compromise the clonogenic and differentiation potential of mesenchymal progenitors, nor its regenerative effect.\n* The ongoing ADICROHN-2 study (PHRC N 2019; EudraCT No. 2019-001948-21) confirming the feasibility of patient recruitment, mastery of the therapeutic approach, and the absence of adverse events related to the experimental treatment.\n* The opportunity for a second FVS injection for patients initially treated but who did not respond to the treatment.\n* The opportunity for a first FVS injection in patients in the placebo arm, thereby providing access to an innovative therapy available to patients included in this trial who are untreated and remain refractory to standard care.\n\nTo avoid compromising the results of the ongoing ADICROHN-2 study, enrolled patients will remain blinded to the treatment arm to which they belonged in the ADICROHN-2 study.",[60],"Crohn Disease (CD)","2026-06-01",{"date":63,"type":37},"2026-06-05",{"date":65,"type":37},"2025-12-30",{"date":67,"type":22},"2028-06-29",{"name":43,"class":44},{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":23,"phases":80,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":45},"100637464","efficacy-of-spinal-cord-stimulation-in-chemotherapy-induced-peripheral-neuropathy-100637464","NCT07579611","Efficacy of Spinal Cord Stimulation in Chemotherapy-Induced Peripheral Neuropathy","Efficacy of Posterior Spinal Cord Stimulation in Chemotherapy-Induced Peripheral Neuropathic Pain: A Multicenter Randomized Crossover Trial","CHEMOSTIM","Inclusion Criteria:\n\n1. Adult patient with chemotherapy-induced painful neuropathy (platinum salts, vincristine, taxanes, alkaloids, epothilone, thalidomide, etc.) evolving for at least 1 year\n2. Indication for spinal cord stimulation validated by a multidisciplinary team meeting according to SFETD\u002FSFNM guidelines\n3. Resistance to pharmacological or topical treatment (failure of at least two therapeutic lines or intolerable side effects: anticonvulsants, antidepressants, capsaicin, etc.)\n4. Pain score \\> 5\u002F10 on numerical scale in the lower limbs\n5. Patient able to understand and give informed consent to the protocol\n6. Patient affiliated to the French Social Security system\n7. Patient able to complete follow-up questionnaires\n\nExclusion Criteria:\n\n* 1\\. Contraindication to spinal cord stimulation:\n* Extensive laminectomy\n* Coagulopathy\n* Intercurrent infections\n* Psychiatric disorders\n\n  2\\. Body Mass Index (BMI) \\> 40\n\n  3\\. Life expectancy \\\u003C 1 year\n\n  4\\. Ongoing pregnancy\n\n  5\\. Patient under guardianship or curatorship\n\n  6\\. Patient already implanted with a spinal cord stimulation device","100 Years",{"count":79,"type":22},68,[25],"Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and debilitating side effect of many cancer treatments. It affects 28 to 48% of patients receiving chemotherapy. Symptoms include tingling, numbness, burning sensations, and pain mainly in the hands and feet. While CIPN often improves after chemotherapy ends, in some patients the pain persists and becomes chronic, severely impairing quality of life, sleep, and daily functioning.\n\nCurrently, no treatment has been shown to prevent CIPN. For patients with chronic pain, duloxetine is the only recommended drug, but its efficacy is limited. When standard medications fail, patients have very few options.\n\nSpinal cord stimulation (SCS) is a well-established neurosurgical technique used to treat various forms of chronic neuropathic pain, including pain after surgery, trauma, or diabetes. In this procedure, thin electrodes are placed in the epidural space near the spinal cord and connected to a small implantable pulse generator. The electrical impulses delivered by the device modulate pain signals in the nervous system.\n\nPreliminary case reports suggest that SCS may be effective in patients with CIPN, but no randomized controlled trial has yet established its value in this specific indication. The CHEMOSTIM study aims to fill this gap.\n\nCHEMOSTIM is a multicenter, prospective, randomized crossover trial. All enrolled patients will undergo SCS implantation. Participants will then be randomized to receive either active stimulation first followed by sham stimulation, or sham stimulation first followed by active stimulation. In the sham phase, the device is implanted but switched off following a simulated programming session, so patients cannot tell which phase they are in.\n\nThe primary outcome is the proportion of patients achieving more than 50% pain reduction on a Visual Analog Scale (VAS) during the active stimulation phase compared to the sham stimulation phase, assessed at 4 months.\n\nSecondary outcomes include changes in quality of life, anxiety and depression, sleep quality, medication use, individualized goal attainment, neurological examination, and nerve conduction studies. The study will also evaluate post-stimulation effects and complications.\n\nEligible patients are adults with chronic CIPN evolving for at least one year, with pain greater than 5\u002F10 in the lower limbs, who have failed at least two lines of pharmacological treatment (antidepressants, anticonvulsants, topical agents, etc.) and whose indication for SCS has been validated by a multidisciplinary team following SFETD\u002FSFNM guidelines.",[83,84,85],"Neuropathic Pain","Chemotherapy-induced Peripheral Neuropathy (CIPN)","Cancer-related Pain",[87,88,89,90],"spinal cord stimulation","posterior cord stimulation","neuropathic pain","Chemotherapy-induced neuropathy","NOT_YET_RECRUITING","2026-05-06",{"date":94,"type":37},"2026-05-12",{"date":96,"type":22},"2026-09-01",{"date":98,"type":22},"2029-05-01",{"name":43,"class":44},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":18,"minAge":108,"maxAge":53,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":123,"leadSponsor":125,"locationsCount":45},"100639620","phase-3-pediatric-prolonged-release-melatonin-for-sleep-disturbances-in-children-and-adolescents-with-anorexia-nervosa-melsom-anorexia-100639620","NCT07576764","Pediatric Prolonged-Release Melatonin for Sleep Disturbances in Children and Adolescents With Anorexia Nervosa (MELSom-ANOREXIA)","Efficacy of Pediatric Prolonged-Release Melatonin (PedPRM) Treatment in Children and Adolescents With Impaired Sleep and Anorexia Nervosa (AN)","MELSomAnorexia","INCLUSION CRITERIA\n\nParticipants aged 6 to 18 years, inclusive, with a diagnosis of Anorexia Nervosa (AN) according to DSM-5 criteria Presence of a sleep problem for at least 1 month, defined as ≤ 6 hours of continuous sleep and\u002For ≥ 0.5 hours sleep latency from lights-off on 3 out of 5 nights, based on participant report (with or without parental assistance according to age), confirmed at D0 by 2-week sleep diary No response to at least 4 weeks of sleep hygiene Negative pregnancy test at baseline, prior to randomization, for female participants of childbearing potential Women of childbearing potential must agree to use a highly effective method of contraception during the study treatment period and for at least 4 weeks after the last dose of study treatment Written informed consent obtained in accordance with the participant's legal status and applicable regulations Affiliation to a social security system or equivalent\n\nEXCLUSION CRITERIA\n\nKnown diagnosis of another significant sleep disorder (e.g. moderate to severe sleep apnea) Use of prohibited medication (z-drugs, melatonin agonist, benzodiazepine, phenylpiperazine class, clomethiazole) or melatonin within 2 weeks prior to screening Declared allergy to melatonin, lactose, or any excipient included in the therapeutic units Pregnant or breastfeeding female participants Unresponsiveness to previous prolonged-release melatonin within the 2 years prior to the study Start of cognitive behavioural therapy (CBT) targeting sleep disturbances or mood disorders within 6 weeks before study inclusion Trans-meridian travel (\\> 2 time zones) within the month before the start of the study Patient under legal protection regimen","6 Years",{"count":110,"type":22},120,[112],"PHASE3","Sleep disturbances are reported by more than 50% of patients with Anorexia Nervosa (AN) and are associated with increased AN severity, psychiatric comorbidities, and poorer quality of life. To date, no pharmacological treatment has been approved or recommended for sleep disorders in children and adolescents with AN. Many drugs are currently prescribed off-label for their sedative side effects, without proven safety or efficacy in this population.\n\nPediatric prolonged-release melatonin (PedPRM, Slenyto®) is the only melatonin formulation approved by the European Medicines Agency (EMA) for chronic insomnia in children aged 2 to 18 years with neurodevelopmental disorders. Its excellent safety profile, absence of tolerance, and long-acting formulation make it a prime candidate for treating sleep disturbances in children and adolescents with AN.\n\nMELSom-ANOREXIA is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb trial. Its primary objective is to assess the efficacy of PedPRM compared to placebo in improving Total Sleep Time (TST) in children and adolescents aged 6 to 18 years with AN and impaired sleep.\n\nParticipants are randomized into two groups: the experimental group receives PedPRM (2 mg or 5 mg depending on response at Day 22) and the control group receives a matching placebo, both administered 0.5 to 1 hour before habitual bedtime for 13 weeks. Sleep is assessed by Sleep Diary and actigraphy. Secondary outcomes include other sleep parameters, AN severity (BMI, EDI-2, EDE-Q), associated symptoms (anxiety, depression, physical activity, executive function, emotionality), and quality of life. Melatonin secretion profiles and specific subgroups (ASD traits, early-onset AN) are also explored.\n\nThe study includes a 2-week run-in period (D-14 to D0) for baseline sleep assessment, followed by 13 weeks of treatment, with visits at D0, D22, and D93. A total of 120 participants will be enrolled across 7 French pediatric psychiatry centers over 24 months.",[115,116],"Anorexia Nervosa","Sleep Disorders in Children",[118],"anorexia","2026-05-04",{"date":121,"type":37},"2026-05-08",{"date":96,"type":22},{"date":124,"type":22},"2029-01-01",{"name":43,"class":44},{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":12,"sex":18,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":45},"100598716","transcriptomic-analysis-of-fibroblasts-and-blood-in-patients-with-rare-diseases-100598716","NCT07075107","Transcriptomic Analysis of Fibroblasts and Blood in Patients With Rare Diseases","Transcriptomic Analysis (RNAseq) of Blood and Fibroblasts to Establish a Diagnosis in Patients With Rare Diseases","ARNseqFibroSan","Inclusion Criteria:\n\n* Male or female, aged 0-99 years\n* Patient with neonatal intellectual disability and\u002For hypotonia followed at one of three inclusion centers\n* Patient or parent has been informed about the study and has signed an informed consent form\n* Genetic analysis by high-throughput DNA sequencing (gene panel, exome, genome) did not identify any abnormality explaining the patient's phenotype.\n* If the patient's phenotype is suggestive of Prader-Willi syndrome or Angelman syndrome: a methylation anomaly test on chromosome 15 was negative.\n* If the patient's phenotype is suggestive of fragile X syndrome: a repeat expansion analysis of the FMR1 gene was negative.\n* If the patient's phenotype is suggestive of myotonic dystrophy type I, DM1: a repeat expansion analysis of the DMPK gene was negative.\n* Patient entitled to or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Patient deprived of liberty\n* Pregnant or breast-feeding woman,\n* The person required to sign the consent form does not understand French\n* Person under guardianship and\u002For curatorship","0 Years","99 Years",{"count":137,"type":22},62,[25],"This study aims to answer a key question in the field of rare genetic diseases by determining the prevalence of deleterious variants at RNA level in undiagnosed patients with intellectual disability and\u002For neonatal hypotonia. This study will put an end to diagnostic erraticism in a number of patients.\n\nFinally, the results of this study will make it possible to compare the two types of tissue used for RNAseq, with a view to facilitating the implementation of this analysis method in the diagnostic setting.",[141],"Rare Genetic Disease",[143,144,145,146,147,148,149,150,151],"genetic analysis by high-throughput DNA sequencing","ARNseq","transcriptomic data","interpretation of sequence variants","Genomic Testing","RNA sequencing data","transcriptome analysis in rare disease","Rare diseases","Intellectual disability",{"date":121,"type":37},{"date":154,"type":37},"2026-03-09",{"date":156,"type":22},"2029-04-30",{"name":43,"class":44},{"id":159,"slug":160,"hasResults":12,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":165,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":179,"leadSponsor":181,"locationsCount":45},"100633050","dysbiosis-of-methanogenic-archaea-and-nanoarchaea-in-the-oral-microbiome-100633050","NCT07521644","Dysbiosis of Methanogenic Archaea and Nanoarchaea in the Oral Microbiome","METHAORAL","Inclusion Criteria:\n\nCase selection criteria:\n\nCases are defined as subjects with oral health vulnerability\n\n* Men or women aged 60 years or older\n* and\u002For immunocompromised individuals without periodontal disease (gingivitis, periodontitis, and peri-implantitis) clinically diagnosed by the dentist during the consultation.\n* Patients who have received information about the study and have not expressed objection\n* Patients who are beneficiaries or eligible for a social security program Control group selection criteria Controls are defined as subjects without oral health vulnerability • Men and women under 60 years of age without periodontal disease (gingivitis, periodontitis, and peri-implantitis) clinically diagnosed by the dentist during the consultation.\n\nThe clinical examination allows for the diagnosis of the absence or presence of periodontal disease, with particular attention to: bleeding on probing, the depth of periodontal pocket(s), tooth mobility, bone destruction in furcation areas, and the assessment of radiographic bone level taking age into account.\n\nExclusion Criteria:\n\n* Patients who are currently excluded from another research protocol at the time the informed consent form is collected.\n* Subjects covered by Articles L1121-5 through L1121-8 of the Public Health Code (minors, adults under guardianship or conservatorship, patients deprived of their liberty, pregnant or breastfeeding women),\n* Men and women with periodontal disease (gingivitis, periodontitis, and peri-implantitis)\n* Men and women with any systemic disease\n* Men and women currently undergoing drug treatment",true,{"count":167,"type":22},250,[25],"Need to improve understanding of oral dysbiosis in the elderly and\u002For immunocompromised individuals (involvement of nanogenes in these dysbiosis) Comparison of dysbiosis identification between results from dental plaque samples and saliva samples (the saliva sample is non-operator-dependent due to its ease of collection). Comparison of the reliability of results obtained with this type of saliva sample versus results obtained with dental plaque samples, which are considered the reference sample type (Antézack 2023).\n\nPrimary objective To estimate the prevalence of dysbiosis in individuals with oral frailty versus individuals without oral frailty.\n\nIn this project:\n\n* Dysbiosis will be defined by the presence of Archaea (Bringuier 2013). For the primary objective, prevalence will be estimated based on dental plaque samples.\n* The population with oral frailty will be defined as individuals over 60 years of age or those with immunosuppression.\n\nHypothesis: The expected proportion of dysbiosis in the population with oral health vulnerability is 40%, whereas the expected proportion of dysbiosis in the population without oral health vulnerability is 20% (Li CL 2009).\n\nSecondary objectives Estimate the prevalence of dysbiosis in the two populations based on a saliva sample\n\n\\- Compare the results from the sample",[171],"Oral Health",[173,174],"oral health issues","without oral health issues","2026-04-08",{"date":177,"type":37},"2026-04-13",{"date":96,"type":22},{"date":180,"type":22},"2029-12-01",{"name":43,"class":44},{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":189,"minAge":53,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":209},"100629641","study-on-the-prevention-of-recidivism-and-the-consequences-of-sexual-violence-suffered-by-female-asylum-seekers-in-france-100629641","NCT07477314","Study on the Prevention of Recidivism and the Consequences of Sexual Violence Suffered by Female Asylum Seekers in France","PREVISEDA","Inclusion Criteria:\n\n* Woman seeking asylum in France\n* Asylum application registered less than 3 months before inclusion.\n* Self-identified female gender.\n* Age ≥ 18 years.\n* Received study information and provided informed consent to participate\n\nExclusion Criteria:\n\n* Re-examination of a previous asylum application.\n* Major cognitive impairment (e.g. dementia or intellectual disability) preventing reliable collection of study outcomes.","FEMALE",{"count":191,"type":22},675,"OBSERVATIONAL","Women seeking asylum (WSA) are overexposed to sexual violence (SV) in their countries of origin, along migration routes, and within host countries. This overexposure does not cease upon arrival in host countries; on the contrary, the first months following arrival are characterised by heightened vulnerability, with an increased incidence of sexual violence, particularly among women with a prior history of victimisation.\n\nSexual violence has major consequences on physical health, mental health, quality of life, and healthcare utilisation, and generates substantial individual and societal costs. International organisations, including the United Nations High Commissioner for Refugees, have identified the prevention of sexual violence and the improvement of care for survivors as public health priorities.\n\nPrevious work suggests that addressing sexual violence within primary care, when embedded in a comprehensive, culturally informed, and coordinated approach integrating medical, psychological, social, and medico-legal dimensions, may contribute to preventing the occurrence or recurrence of sexual violence in host countries. However, no comparative study has yet evaluated the effectiveness of such a coordinated model of care on the prevention of sexual violence among women seeking asylum, nor assessed its efficiency or transferability.\n\nThe primary objective of this study is to evaluate the effectiveness of a coordinated, transcultural, multidisciplinary outpatient care model on the prevention of sexual violence occurring in host European countries among women seeking asylum.",[195,196,197,198,199,200],"Sexual Violence","Refugee Health","Physical Health","Mental Health","Quality of Life","Access to Recommended Healthcare","2026-03-17",{"date":203,"type":37},"2026-03-19",{"date":205,"type":22},"2026-04",{"date":207,"type":22},"2028-09",{"name":43,"class":44},6,{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":165,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":238},"100618195","occupational-exposure-to-antineoplastic-drugs-among-physiotherapists-in-healthcare-settings-100618195","NCT07328464","Occupational Exposure to Antineoplastic Drugs Among Physiotherapists in Healthcare Settings","Occupational Exposure to Antineoplastic Drugs Among Physiotherapists in Healthcare Settings: From Assessing Internal Contamination to Implementing Co-constructed Prevention Measures","KINEMAC","Inclusion Criteria:\n\nInclusion criteria for individuals eligible for inclusion in the study:\n\nBeing a state-certified physiotherapist or hold an equivalent qualification, Working in one of the healthcare departments selected for the study, Being a man or woman aged 18 or over, Having received information about the study and not expressed any opposition to participating in it\n\nInclusion criteria for each physiotherapist observation visit as part of the internal contamination study:\n\nPerform at least one physiotherapy treatment during this visit that must meet all of the following five criteria:\n\nThe physiotherapy treatment taken into account for this observation visit must be carried out in one of the healthcare departments selected for the study, This physiotherapy treatment being at least one of the following: massage and\u002For manual\u002Flymphatic drainage and\u002For limb mobilisation and\u002For respiratory physiotherapy, This physiotherapy treatment being performed on a patient who has received intravenously at least one of the seven antineoplastic drugs studied, This physiotherapy treatment being performed within 4 to 72 hours of the start of intravenous administration of the antineoplastic drug(s) studied, This physiotherapy treatment is performed on a patient who is not in septic isolation and\u002For in a protected area.\n\nInclusion criteria for each physiotherapist observation visit as part of the external contamination study:\n\nPerform at least one physiotherapy treatment during this visit that must meet all of the following five criteria:\n\nThe physiotherapy treatment taken into account for this observation visit, must be carried out in one of the healthcare departments selected for the study, This physiotherapy treatment being at least one of the following: massage and\u002For manual\u002Flymphatic drainage and\u002For limb mobilisation and\u002For respiratory physiotherapy, This physiotherapy treatment being performed on a patient who has received intravenously at least one of the twelve antineoplastic drugs studied, This physiotherapy treatment being performed within 4 to 72 hours of the start of intravenous administration of the antineoplastic drug(s) studied, This physiotherapy treatment is performed on a patient who is not in septic isolation and\u002For in a protected area.\n\nExclusion Criteria:\n\nBeing a physiotherapy student, Being treated with one of the 12 antineoplastic drugs studied during the study or having been treated with one of them in the 2 months prior to the start of the study, Having a person and\u002For animal in their household who has been treated with one of the 12 antineoplastic drugs during the study or in the 2 months prior to the start of the study.\n\nPhysiotherapists who meet any of the following exclusion criteria for the observation visit will not be eligible for inclusion in the internal contamination assessment:\n\nBeing assessed for the internal contamination on the same day as the external contamination assessment, Being treated with one of the seven antineoplastic drugs studied during the study or having been treated with one of them during the two months preceding the observation visit, Having a person and\u002For animal in their household who is being treated with one of the seven antineoplastic drugs during the study or in the two months prior to the observation visit.\n\nExclusion criteria for each observation visit as part of the external contamination study\n\nPhysiotherapists who meet any of the following exclusion criteria for the studied physiotherapy treatment cannot be included in the external contamination assessment:\n\nBeing assessed for the external contamination on the same day as the internal contamination assessment, Performing this physiotherapy treatment while wearing a long-sleeved gown and\u002For long-sleeved overgown, Performing this physiotherapy treatment while using a cream and\u002For gel and\u002For oil, Being treated oneself with one of the 12 antineoplastic drugs studied during the study or having been treated with one of them during the 2 months preceding the physiotherapy treatment, Having a person and\u002For animal in their household who is being treated with one of the 12 antineoplastic drugs during the study or in the 2 months prior to the physiotherapy treatment.",{"count":219,"type":22},20,"Many antineoplastic drugs are considered \"hazardous to handle\" for healthcare professionals, notably because of their carcinogenic, mutagenic and\u002For reprotoxic effects. Occupational exposure occurs mainly through the cutaneous route, either by direct contact with the drug and\u002For indirectly through contact with treated patients and their excreta, or through contact with contaminated surfaces or textiles.\n\nTo date, physiotherapists have been little studied in terms of occupational exposure, even though they frequently perform care practices (massage, lymphatic drainage, limb mobilisation, respiratory physiotherapy) involving direct, prolonged and sustained skin contact with patients treated with antineoplastic drugs; these compounds may be eliminated in the sweat of the treated patient for several days after administration.\n\nIn this context, the present study aims to assess the occupational exposure of physiotherapists to antineoplastic drugs in healthcare settings. The primary objective is to estimate the prevalence of internal contamination of physiotherapists by antineoplastic drugs after performing one of the care practices (massage, lymphatic drainage, limb mobilisation, respiratory physiotherapy) selected for the study, in patients receiving intravenous treatment with antineoplastic drugs.\n\nThe secondary objectives are to describe for each antineoplastic drug studied the prevalence, the frequency of internal contamination of physiotherapists, and urinary concentration levels, to characterise the circumstances of exposure and the personal protective equipment worn, to describe the prevalence and the frequency of external cutaneous contamination on the hands and forearms of physiotherapists after performing an exposing care practice, to quantify this external cutaneous contamination, to identify the factors associated with internal and external contamination, and to co-develop preventive measures in collaboration with physiotherapists and stakeholders and to assess their acceptability.\n\nThis study is a non-interventional (RIPH3), cross-sectional and multicenter study conducted at AP-HM (Public Assistance for Marseille hospitals) and Bordeaux University Hospital (CHU de Bordeaux). Twenty physiotherapists will be included in this study. Internal contamination will be assessed over 100 observation visits and external contamination over 70 observation visits (all participants combined). Observation visit include at least one \" an exposing care practice\" (massage, lymphatic drainage, limb mobilisation, respiratory physiotherapy) performed on a patient who received an intravenous antineoplastic drug from a predefined list, within a time window of 4 to 72 hours after the start of injection.\n\n\\- Internal contamination assessment (urine samples collection) For each observation visit, two urine samples of the physiotherapist participant will be collected: one sample within the 3 hours preceding the start of the work shift, and a second sample 6 to 10 hours after the end of the shift (or the next morning after waking up).\n\nData on exposure, activity and preventive practices (personal protective equipments worn) will be collected using an administered questionnaire (CRF). Information on the antineoplastic drugs administered to the patient receiving care by the physiotherapist will also be collected.\n\n\\- Cutaneous external contamination assessment (dermal wipe sampling) For each observation visit, the physiotherapist will apply a standardized hands and forearms washing protocol, observed by the clinical research technician. Then, cutaneous swab samples will be taken immediately after the washing.\n\nThe physiotherapist will then perform an exposing care practice, limiting contact with the environment (e.g., door handles\u002Fsurfaces), and new samples will be taken immediately after the exposing care practice, without prior decontamination of hands and forearms. A total of eight cutaneous swab samples (four before and four after an exposing care practice) will be collected per observation visit, according to a protocol validated by the reference laboratory.\n\nThe assessment of cutaneous external contamination of physiotherapists will be evaluated during visits separate from those used to study internal contamination.\n\nThe expected outcomes of this study are: an individual assessment of exposure and potential internal contamination and\u002For external dermal contamination, for each physiotherapist; traceability of exposure in occupational health medical records, for each physiotherapist; improved knowledge on the proportion of contaminated physiotherapists (prevalence and frequency) and knowledge on urinary and cutaneous concentration levels of antineoplastic drugs in physiotherapists; increased awareness among physiotherapists regarding these exposures; implementation of co-developed preventive actions aiming to reduce exposures to the lowest possible level; and improved professional practices and working conditions.",[222],"Internal and External Contamination of Physiotherapists by Antineoplastic Drugs",[224,225,226,227,228,229],"Internal contamination","external contamination","physiotherapists","antineoplastic drugs","prevention measures","healthcare","2026-03-13",{"date":232,"type":37},"2026-03-16",{"date":234,"type":22},"2026-03",{"date":236,"type":22},"2027-03",{"name":43,"class":44},2,{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":248,"briefSummary":249,"conditions":250,"keywords":253,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":260,"leadSponsor":262,"locationsCount":45},"100607727","predicting-reactions-and-effects-of-drugs-immunotherapy-and-complications-through-oncosafety-predicto-clinical-study-100607727","NCT07192315","Predicting Reactions and Effects of Drugs Immunotherapy and Complications Through Oncosafety (PREDICTO Clinical Study)","PREDICTO","Inclusion Criteria:\n\n* Adult patient (≥18 years old)\n* Patient presenting an histologically or cytologically confirmed solid tumour malignancy\n* Patient scheduled to receive his\u002Fher first infusion of immunotherapy with anti-PD1, anti-PDL1, anti-CTLA4, anti-LAG3, alone or in combination, as part of standard care, in all validated solid oncology indications.\n* Patient must have at least one measurable lesion according to RECIST 1.1 criteria\n* Patient treated at AP-HM in one of the CEPCM-affiliated departments.\n* Patient able to comply with study procedures and follow-up schedule\n* Patient who has been informed about the study and signed the consent form\n* Patient who is a beneficiary or entitled beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Patient previously treated with ICIs\n* Patient whose treatment plan includes targeted therapy, chemotherapy or any other systemic treatment in combination with ICI\n* Patient included in a trial with an experimental molecule\n* Patient has an active autoimmune disease or any other pathology requiring systemic corticosteroid therapy at more than 10 mg prednisone equivalent per day or any other immunosuppressive drug\n* Patients with a history of organ transplantation, hematopathy or hematopoietic stem cell transplantation\n* Patient with history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator.\n* Patient in emergency situations, persons deprived of their liberty by judicial or administrative decision, adults subject to legal protection measures, or persons who are unable to give their consent, or pregnant or breastfeeding.",{"count":247,"type":22},160,[25],"Immune Checkpoint Inhibitors (ICI) have revolutionized cancer therapy, providing unprecedented responses in a wide range of malignancies. However, they induced various immune-related adverse events (iRAE) that can be life-threatening. About 20% of patients treated with an ICI monotherapy, and up to 60% of patients treated with a combination of ICIs, experienced a severe iRAE. Most side effects are reversible if managed early, but can affect survival and quality of life, leading to treatment interruptions or hospitalization. Some of these irAEs, particularly those affecting hormonal functions, may be irreversible and persist even after treatment discontinuation.\n\nThe development of predictive biomarkers of such toxicities is an unmet medical need. The variety of mechanisms involved in iRAE, and the lack of effective animal models, could probably explain why the topic remains largely unexplored. To date, some biomarkers predictive of the occurrence of iRAE, irrespective of the type of organ affected, have been identified by state-of-the-art techniques on small cohorts prior to treatment initiation, but none is individually robust enough to be used in daily practice.\n\nWe hypothesize that a signature derived from the integrative analysis of various biological parameters (immunomonitoring, auto-immunity features, viral monitoring, microbiota monitoring, fragmentome analysis, pharmacokinetics, radiomics and genetics), available in routine hospital practice, could answer this question, and thus enable the development of specific prevention strategies\n\nThe objectives are :\n\nPrimary objective:\n\nIdentify a baseline predictive signature for severe iRAE, irrespective of the type of organ affected.\n\nSecondary objectives:\n\n* Identify a predictive signature for severe iRAE including baseline and T1 data, irrespective of the type of organ affected.\n* Identify a baseline predictive signature for organ-specific severe iRAE.\n* Identify a predictive signature for organ-specific severe iRAE including baseline and T1 data.\n* Identify a baseline predictive signature for severe iRAE, irrespective of the type of organ affected, for patient receiving an anti-PD(L)1 in monotherapy.\n* Identify a baseline predictive signature for severe iRAE, irrespective of the type of organ affected, for patient receiving an anti-PD(L)1 in combination.\n* Identify a baseline predictive signature for severe iRAE, irrespective of the type of organ affected, for each specific immunotherapy received.\n* Compare the predictive signatures between responders and non-responders according to RECIST 1.1 in order not to overlook the influence of clinical response on the variability observed.\n* Describe the results obtained for each biological parameter between severe irAEs and non-severe irAEs patients.\n* Describe patient-reported outcomes and quality of life parameters.",[251,252],"Solid Tumor Malignancies","Solid Cancers",[254,255,256],"immuno-induced adverse events","Immune checkpoint inhibitor","baseline predictive signature","2026-03-11",{"date":230,"type":37},{"date":205,"type":22},{"date":261,"type":22},"2028-01",{"name":43,"class":44},{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":268,"eligibilityCriteria":269,"healthyVolunteers":165,"sex":18,"minAge":108,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":23,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":45},"100582920","identification-of-anti-hif-1alpha-autoantibodies-in-patients-with-anorexia-nervosa-and-characterization-of-their-pathogenic-potential-in-undernutrition-associated-hepatic-cytolysis-100582920","NCT06869590","Identification of Anti-HIF 1alpha Autoantibodies in Patients With Anorexia Nervosa and Characterization of Their Pathogenic Potential in Undernutrition-associated Hepatic Cytolysis","HIAM","Inclusion Criteria:\n\nExperimental group:\n\n* Male or female, 6 to 65 years of age\n* Anorexia nervosa diagnosed according to DSM-5 criteria\n* Presence of undernutrition according to HAS 2019 criteria\n* Patient having received information about the study and having signed an informed consent form\n* Beneficiary or beneficiary of a social security scheme\n\nControl group:\n\n* Minor patients :\n\n  * Male or female strictly under 18 years of age\n  * Patients undergoing scheduled non-inflammatory surgery (orthopedic, ENT, etc.)\n  * Patients who have been informed about the study and have signed an informed consent form.\n  * Patients who are beneficiaries or entitled beneficiaries of a social security scheme.\n* Patients without anorexia with livers cytolysis :\n\n  * Male or female between 18 and 65 years of age\n  * With hepatic cytolysis determined by an ALT value at least equal to twice the normal value\n  * Patient having received information about the study and having signed an informed consent form\n  * Patient who is a beneficiary or eligible beneficiary of a social security scheme.\n* samples Etablissement Français de don de sang: no specific criteria\n\nExclusion Criteria:\n\n* Patient in a period of exclusion from another research protocol at the time consent is signed.\n* Opposition of patient and parents or legal guardians\n* Psychiatric disorder preventing patient consent to study\n* Person unable to understand the French language\n* Subjects covered by articles L1121-5 to 1121-8 of the French Public Health Code (minors, adults under guardianship or trusteeship, patients deprived of their liberty, pregnant or breast-feeding women).","65 Years",{"count":167,"type":22},[25],"Anorexia nervosa (AN) is a psychiatric disorder belonging to the eating disorders (EDs). It is internationally recognized as a priority for improving health care. Among the markers of severity of undernutrition is hepatic cytolysis. Around 30-50% of patients with AN present with hepatic cytolysis, of variable intensity, and usually associated with severe undernutrition. In a previous study, we demonstrated the presence of autoantibodies against HIF1alpha (Hypoxic inducible Factor 1 alpha) in 22% of cases in a sample of patients with AN. HIF1alpha (HIF1a) is a major transcription factor involved in the regulation of satiety and hunger. These autoantibodies were positive in 80% of AN patients with hepatic cytolysis. Taken together, these data led us to hypothesize an anti-HIF1a autoimmune mechanism in AN, potentially involved in the patients' hepatic cytolysis.\n\nThis pioneering study, demonstrating the existence of anti-HIF1a autoantibodies, was carried out on a population of 18 patients with AN. To extend investigator's hypothesis, these results need to be confirmed on a larger number of patients, thus increasing the number of patients with AN and hepatic cytolysis. To determine the relevance of these autoantibodies in AN, \"healthy\" subjects and patients without AN but with hepatic cytolysis should be tested in parallel. Finally, the in vitro pathogenic potential of autoantibodies can be confirmed on a larger scale and studied in greater detail.\n\nThe main aim of our study is to evaluate the association between the presence of anti-HIF1a autoantibodies (AAHIF) and that of hepatic cytolysis in patients with anorexia nervosa and undernutrition.\n\nThis study is a prospective, cross-sectional, descriptive, multicenter, 2-arm study.\n\n250 patients will be included. Experimental group (n=100)\n\n* Patients with anorexia nervosa and undernutrition with hepatic cytolysis (CH) (n=70)\n* Patients with anorexia nervosa and undernutrition without hepatic cytolysis (n=30) Comparator control groups (n=150)\n* Control patients under 18 years of age, treated at the CHU de la Timone for scheduled non-inflammatory surgery (orthopedic, ENT, etc.) (n=50): Minor patients\n* Patients (children and adults) with hepatic cytolysis without anorexia nervosa (n=50): Patients without AN with CH\n* Samples from French blood donation establishment: control group consisting of biological blood samples from healthy individuals from the Etablissement Français du Sang (n=50)",[275],"Hepatic Cytolysis",{"date":230,"type":37},{"date":278,"type":37},"2026-02-02",{"date":280,"type":22},"2029-05-24",{"name":43,"class":44},{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":23,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":45},"100576589","involvement-of-archaea-in-carious-disease-100576589","NCT06787261","Involvement of Archaea in Carious Disease","CARIARCHAE","Inclusion Criteria:\n\n* Male or female of legal age.\n* Patient who is a beneficiary or entitled beneficiary of a social security\n* Patient under the care of the Restorative and Preventive Dentistry of the PROMOD - Timone Dentistry Unit.\n* Patients capable of giving written consent.\n\nExclusion Criteria:\n\nPatient in a period of exclusion from another research protocol at the time of signing the consent form, Subjects covered by articles L1121-5 to 1121-8 of the Public Health public health code (minor patients, patients of full age under guardianship, patients deprived of their liberty, pregnant or breast-feeding), A person who does not have a sufficient command of reading and understanding of the French language to be able to consent to take part in the research Presence of periodontitis (gingivitis not being a criterion for a criterion for non-inclusion). Antibiotics taken in the previous month. Use of mouthwash in the previous 7 days.",{"count":290,"type":22},200,[25],"Dental caries is a major public health probleme the result of hard tissue demineralization and oral microbiota changes.\n\nMethanogenic archaea, mainly Methanobrevibacter oralis, are associated with various oral problems, including pathologies periodontal.\n\nPrevious research has not really studied the Archaea in carious lesions, hence the importance of our study.\n\nOur study aims to explore their potential role in the the development of caries by analysing their prevalence and their quantification in relation to the carious risk individual. The aim is to improve understanding of the Cavity microbiology to advance management of this pathology in terms of prevention or of treatment.\n\nOur team is particularly competent in the field of Archaea, especially in the cultivation of Archaea methanogens since we have a dedicated platform. We also discovered the first human Nanoarchaea, opening up a whole new possible search field.",[294],"Dental Caries",[296],"Dental caries","2026-02-20",{"date":299,"type":37},"2026-02-23",{"date":301,"type":37},"2026-02-19",{"date":303,"type":22},"2028-02-01",{"name":43,"class":44},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":45},"100503566","association-between-renal-regional-oxygen-saturation-measured-by-near-infrared-spectroscopy-and-postoperative-renal-failure-after-lung-transplantation-surgery-a-pilot-study-100503566","NCT05836922","Association Between Renal Regional Oxygen Saturation Measured by Near-InfraRed Spectroscopy and Postoperative Renal Failure After Lung Transplantation Surgery: A Pilot Study","SO-AKI-TP","Inclusion Criteria:\n\n* patient undergoing a lung transplant (mono or bi-transplantation)\n* Age \\>= 18 years\n* Affiliated to the French social security system\n\nExclusion Criteria:\n\n* Renal anatomical abnormality likely to induce a misleading NIRS signal: single kidney, polycystic kidney disease.\n* Expression of opposition to participation in the research protocol.\n* Hyperbilurbinemia \\> 17mmol\u002Fl\n* Preoperative Extra Corporeal Membran Oxygenation (ECMO).\n* Preoperative mechanical ventilation",{"count":313,"type":22},80,"Complications after lung transplantation are almost ubiquitous, among which postoperative acute renal failure may represent more than 50% of lung transplant patients and require extrarenal purification in 5 to 13% of cases.\n\nMultiple factors are associated with postoperative acute renal failure. These factors can be classified into preoperative, intraoperative, and postoperative factors. While some postoperative complications are explained by donor and recipient factors, the literature suggests that certain intraoperative events represent modifiable or avoidable risk factors that could be targeted by therapeutic interventions to reduce the risk of postoperative acute renal failure. Some of these factors (intraoperative hemodynamic instability, significant bleeding or hypoxemia) can generate renal hypoxic aggression, alone or in combination. However, to date, there is no validated tool available at the patient's bedside during surgery to detect renal hypoxia or guide interventions to restore renal perfusion during surgery. Yet, as recent recommendations suggest, intraoperative renal protection is an important axis for improving the outcome of lung transplant patients, to the extent that the recommendations of Marczin et al. recommend the establishment of a renal prevention protocol for each patient. Without a tool to guide this plan intraoperatively, anesthesia teams can't establish a renal prevention protocol. This research aims to establish whether renal NIRS is a reliable tool for monitoring intraoperative renal hypoxic aggression predictive of postoperative renal failure.\n\nNear-infrared spectroscopy (NIRS) is an optical technology that allows non-invasive measurement of tissue oxygen saturation. This technique is commonly used for intraoperative monitoring of cerebral perfusion in adults and children. Some studies have shown that regional renal oxygen saturation (renal rSO2) measured by NIRS during aortic-coronary bypass surgery under extracorporeal circulation (ECC) is correlated with renal venous oxygen saturation measured by catheterization. It is also associated with the risk of postoperative acute renal failure in patients undergoing cardiac surgery under ECC. However, there are no equivalent data in lung transplant patients, who frequently present with postoperative acute renal failure. In the available literature, no clear threshold of renal desaturation has been established. Because it is assumed that the depth of renal desaturation can be particularly deleterious, in addition to desaturation time, the investigator have chosen to retain in this project the integral of time and magnitude spent under a renal desaturation threshold, aggregated into a renal hypoxia index, during the intraoperative period.\n\nThe primary objective of this research is to demonstrate the usefulness of measuring the intraoperative renal hypoxia index in predicting the risk of early postoperative acute renal failure",[316,317],"Lung Transplant; Complications","Acute Kidney Injury",{"date":299,"type":37},{"date":320,"type":37},"2024-03-23",{"date":322,"type":22},"2026-09-28",{"name":43,"class":44},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":18,"minAge":331,"maxAge":332,"enrollmentInfo":333,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":7},"100625145","determinants-and-consequences-of-the-transition-to-adulthood-for-adolescents-with-severe-haemophilia-transhemo-2-an-ancillary-study-to-the-transhemo-project-100625145","NCT07418827","Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project","TRANSHEMO2","Inclusion Criteria:\n\n* Young adults who participated in the TRANSHEMO project during adolescence and who are currently aged 20-29 years;\n* Young adults with severe haemophilia (haemophilia A or B);\n* Young adults registered in the FranceCoag registry;\n* Young adults who have received the participant information sheet for the TRANSHEMO 2 project;\n* Young adults who did not object to participation in the present study.\n\nExclusion Criteria:\n\n* patients with comprehension difficulties;\n* patients who are unable to read and\u002For write;\n* patients who express opposition to participation in this study.","20 Years","29 Years",{"count":334,"type":22},75,"Haemophilia is a rare genetic disorder which, in its severe form and in the absence of treatment, can be life-threatening. Since the 1960s and the introduction of coagulation factor concentrates, the life expectancy of people with haemophilia has increased rapidly. Today, for most affected individuals, the disease is experienced as a chronic condition.\n\nThe transition process enabling adolescents and young adults (AYA) with a chronic disease to move into adult life can be complex, as they must face all the changes experienced by AYA in general, combined with issues related to their chronic condition and its management.\n\nA successful transition involves a transfer of responsibility from parents to AYA regarding the management of their health condition, as well as the acquisition by AYA of knowledge, skills and autonomy. A difficult transition may lead to decreased adherence to follow-up or treatment, deterioration of overall health status and\u002For quality of life, or difficulties in entering adult life.\n\nIn this context, the national cross-sectional study TRANSHEMO was initiated in 2017. Its objective was to compare adherence to healthcare management between two groups of AYA with severe haemophilia (adolescents \\[for whom the transition is ongoing\\] versus young adults \\[for whom the transition may have been completed\\]), and to identify the determinants of this adherence. The results showed that young adults had a lower adherence rate than adolescents (82.2% vs. 61.2%, p\\\u003C0.001). Among the determinants studied, being a young adult, having repeated at least one school year, and presenting psychological and emotional difficulties were factors that had a negative effect on adherence to healthcare management. However, the cross-sectional nature of the study represents a limitation that restricts causal inference. Complementing this project with a longitudinal study would address this limitation.\n\nThe results obtained from this new study (TRANSHEMO 2) may contribute to the literature by providing insights into both the determinants of sustained adherence to healthcare management among adolescents with severe haemophilia who become young adults, and the associations between these determinants.\n\nThe longitudinal design of the project will allow the establishment of a higher level of causal inference between the maintenance of adherence during the transition to adult life and its determinants, which represents a major epidemiological strength. Moreover, results addressing the issue of transition in the context of chronic diseases and derived from longitudinal studies remain scarce, making the findings of this project particularly original. Finally, haemophilia, a relatively frequent condition among rare diseases, could represent an interesting model for understanding the impact of transition in this type of pathology.\n\nStudy hypothesis The extent of the reduction in adherence to healthcare during the transition process, and\u002For the determinants of the maintenance of adherence identified in the longitudinal TRANSHEMO 2 project, may differ from those highlighted in the original cross-sectional TRANSHEMO project.\n\nSpecific aims\n\nMain objective:\n\nTo compare the rate of adherence to healthcare among adolescents who participated in the TRANSHEMO project, using data collected during the original TRANSHEMO study when they were adolescents (before transition) and data to be collected as part of the TRANSHEMO 2 study when they have become young adults (after transition).\n\nSecondary objective:\n\nTo identify the determinants of the maintenance of this adherence and the associations between these determinants, within the framework of a longitudinal study.",[337],"Haemophilia",[339,340,341,342,343],"haemophilia","young adult","cohort study","genetic disorder","healthcare management","2026-02-11",{"date":346,"type":37},"2026-02-18",{"date":348,"type":22},"2026-02",{"date":350,"type":22},"2027-06",{"name":43,"class":44},{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":359,"minAge":53,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":23,"phases":363,"briefSummary":364,"conditions":365,"keywords":367,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":373,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":45},"100566645","local-anesthesia-with-schelin-catheter-in-rezum-treatment-a-randomized-controlled-trial-100566645","NCT06657872","Local Anesthesia With Schelin Catheter in Rezum Treatment: a Randomized Controlled Trial","LOCALVAPOR","Inclusion Criteria:\n\n* Patients referred for symptomatic benign prostatic hyperplasia (BPH)\n* Men between 45 and 80 years of age\n* IPSS \\> 13\n* Qmax \\\u003C15 ml\u002Fs\n* Prostate volume between 30 and 80 g on ultrasound\n* Patient able to understand study details, benefits and risks\n* Patient able to give informed consent\n* Beneficiary of or affiliated to the French social security system\n* Patient having signed an informed consent form\n\nExclusion Criteria:\n\n* Patients with a history of prostate cancer\n* Patient with history of BPH surgery\n* Patients with a history of neurological bladder disease\n* Patient with history of urethral stricture\n* Patient with history of penile implants\n* Patient with history of pelvic irradiation\n* Patient with a symptomatic urinary tract infection in the 10 days prior to surgery\n* Presence of bladder stones on ultrasonography\n* Patient allergic to lidocaine 2% or any medication used in the pre-operative protocol (anxiolytics, analgesics and non-steroidal anti-inflammatory drugs)\n* Patient under guardianship or curatorship\n* Protected patient, deprived of liberty\n* Patient with a neurological and\u002For psychiatric disorder making it impossible to understand the terms of the study and to sign an informed consent form","MALE","80 Years",{"count":362,"type":22},24,[25],"In a pilot study, water vapor therapy (RezumTM, Boston Scientific Corporation, Marlborough, MA) was proposed as a minimally invasive procedure for benign prostatic hyperplasia, but often requiring oral ± intravenous sedation or a transrectal prostatic block. Therefore, pain management during Rezum therapy remains a challenge and may lead to the use of pain control protocols and general anesthesia, limiting in some ways the concept of a minimally invasive ambulatory surgical approach. The Schelin® catheter (ProstaLund AB, Lund, Sweden), approved by the European Medicines Agency, is a device for injecting analgesic drugs directly into the prostate via the trans-urethral route, providing more effective local anesthesia and avoiding the need for transrectal route or general anesthesia. This catheter is therefore of crucial importance in offering to our patients an ultra-minimally invasive treatment, associated with a reduction in room occupancy time, outpatient surgery time, a procedure performed independently of the anesthesia team, and for the patient, an accelerated post-operative recovery. Our hypothesis is that the REZUM procedure under local anesthesia could be associated with a \\>20% reduction in operating room occupancy time compared to procedures performed under general anesthesia.",[366],"Benign Prostatic Hyperplasia",[368,369,370,371],"REZUM","MIST","general anesthesia","local anesthesia","2026-02-10",{"date":344,"type":37},{"date":375,"type":37},"2025-03-24",{"date":377,"type":22},"2026-11-24",{"name":43,"class":44},{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":359,"minAge":387,"maxAge":388,"enrollmentInfo":389,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":45},"100550428","identification-of-markers-of-poor-clinical-prognosis-in-sepsis-by-epigenetic-analysis-100550428","NCT06446947","Identification of Markers of Poor Clinical Prognosis in Sepsis by Epigenetic Analysis","Identification de Marqueurs de Mauvais Pronostic Clinique du Sepsis Par Analyse épigénétique.","EPISEPSIS","Inclusion Criteria:\n\n* Male patients,\n* Patients between 45 and 75 years of age,\n* Patients undergoing major esophageal or digestive carcinological surgery,\n* Patients with post-operative gram-negative bacterial sepsis (proven or suspected in the context of organ failure).\n\nExclusion Criteria:\n\n* patients under 45 and aged 76 and over,\n* female patients,\n* non-carcinological or minor surgery,\n* non-esophageal or non-digestive surgery,\n* Gram-positive bacterial or fungal infections in the absence of associated BGN,\n* patients with hematological cancer,\n* immunocompromised patients,\n* septic surgery (surgical site infection),\n* patients expressing opposition to data collection and analysis (clinical and\u002For biological) within the regulatory framework of the study,\n* patients under guardianship or curatorship,\n* patients not affiliated to a social security system or equivalent in France,\n* patients deprived of their liberty.","45 Years","75 Years",{"count":7,"type":22},"Sepsis is a multifactorial syndrome characterized by a dynamic course and a clinical outcome dependent on several factors, and responsible for one in five deaths worldwide. The aim of this trial is to identify new prognostic markers for the progression of sepsis to septic shock, by comparing epigenetic markers between patients who have or have not developed severe forms of sepsis.\n\nThe main objective of this preliminary study is to identify prognostic markers for the progression of sepsis to septic shock, i.e. to compare targeted markers between subjects with sepsis who progress to septic shock versus subjects with sepsis who do not progress to septic shock.",[392,393,394],"Sepsis Syndrome","Septic Shock","Sepsis",{"date":396,"type":37},"2026-02-12",{"date":398,"type":37},"2025-03-20",{"date":400,"type":22},"2026-09-30",{"name":43,"class":44},{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":165,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":409,"targetDuration":4,"studyType":23,"phases":411,"briefSummary":412,"conditions":413,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":372,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":45},"100336215","speckle-tracking-echocardiography-for-the-prediction-of-weaning-failure-100336215","NCT03657524","Speckle Tracking Echocardiography for the Prediction of Weaning Failure","Combined Thoracic Ultrasound Using Speckle Tracking for the Prediction of Weaning Failure : a Prospective Multicenter Study","Inclusion Criteria:\n\n\\- Patients hospitalized in intensive care unit under mechanical fulfilling the criteria of ventilation weaning trial.\n\nExclusion Criteria:\n\n* Less than 18 years old.\n* Pregnancy\n* Non sinusal cardiac rhythm\n* Neuro Myopathy\n* Tracheotomy\n* Lack of echogenicity to perform at least a four chamber apical view",{"count":410,"type":22},110,[25],"Deciding the optimal timing for extubation in patients who are mechanically ventilated can be challenging, and traditional weaning predictor tools are not accurate. Recent studies suggest that isolated sonographic assessment of the respiratory and cardiac function (ie diastolic function and filling pressure), in mechanically ventilated patients may assist in identifying patients at risk of weaning failure. Recently, the association of conventional echocardiography and lung ultrasound showed promising results for the prediction of post extubation distress. Speckle Tracking is an emerging tool in intensive care medicine that has never been investiguated for the prediction of weaning failure. It could early detects diastolic dysfunction and and elevated filling pressure. Of more, speckle tracking is known to be less operator dependant. The main objective of our study is to evaluate the diagnosis accuracy of speckle tracking echocardiography performed during a weaning trial to predict weaning failure. The secondary objectives are to assess the diagnosis accuracy of combined heart and lung ultrasound to predict weaning failure.",[414],"Weaning Failure of Mechanical Ventilation",{"date":396,"type":37},{"date":417,"type":37},"2019-05-20",{"date":419,"type":22},"2026-05-21",{"name":43,"class":44},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":23,"phases":431,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":437,"completionDateStruct":438,"leadSponsor":440,"locationsCount":45},"100624176","methotrexate-early-toxicity-monitoring-100624176","NCT07406230","Methotrexate Early Toxicity Monitoring","Methotrexate Early Toxicity Monitoring in Primary Central Nervous System Lymphomas (PCNSL)","METoxiM","Inclusion Criteria:\n\n* Adult patient aged 18 years or older,\n* Patient with a primary lymphoma of the central nervous system, histologically or cytologically proven,\n* Patient eligible for high-dose methotrexate treatment (\\> at 500 mg\u002Fm 2), in the first line of treatment,\n* Patient who has received information regarding the study and signed an informed consent,\n* Patient beneficiary or entitled to a social security scheme.\n\nExclusion Criteria:\n\n* Patient treated with a therapy complementary to the standard 1st-line treatment based on high-dose MTX as part of a clinical research protocol,\n* Patient in a period of exclusion from another research protocol at the time of signing consent,\n* Subjects covered by articles L1121-5 to 1121-8 of the Public Health Code (minor patient, adult patient under guardianship or curatorship, patient deprived of liberty, pregnant or breastfeeding woman).",{"count":430,"type":22},50,[25],"High-dose methotrexate (MTX) is the main componement of first line treatment in primary central nervous system lymphoma. Renal toxicity is the main dose limiting toxicity because of major MTX elimination by the kidneys. MTX crystallizes in renal tubules, leading to a renal failure (RF) and further delaying its elimination. When RF occurs, MTX accumulates, prolonging the duration of treatment exposure. MTX prolonging exposure can cause life-threatening complications and delay further treatments in the patient. Preventive measures have been developped, such as alkaline fluid hyperhydration and folic acid administration, to try to reduce the risk of these adverse events.\n\nIn suspected severe RF in link to MTX is suspected, glucarpidase can be administared. However, this is an expensive treatment and not all patients recover normal renal function despite its use.\n\nMTX is an essential treatment for the management of PCNSL which is currently a curable disease especially in patients who are able to receive a consolidation treatment as thiotepa-based intensive consolidation followed by autologous stem cell transplantation (IC-ASCT). IC-ASCT requires a normal renal function, which could be impaired by severe RF secondary to MTX.\n\nThe purpose of the study is to investigate how early dosing MTX could be used to simulate late concentrations. Early monitoring of MTX elimination could be implemented to identify patients at risk of delayed elimination and thus introduce rapid mesures as early administration of glucarpidase.",[434],"Primary Central Nervous System Lymphoma","2026-02-05",{"date":396,"type":37},{"date":205,"type":22},{"date":439,"type":22},"2027-12",{"name":43,"class":44},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":18,"minAge":449,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":452,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":462,"locationsCount":463},"100530211","drowning-related-acute-respiratory-failure-100530211","NCT06183827","Drowning-related Acute Respiratory Failure","Evaluation of Non-Invasive Ventilation\u002FContinuous Positive Airway Pressure for Drowning-related Acute Respiratory Failure","CPAPDROWNING","Inclusion Criteria:\n\n* Man\u002Fboy or woman\u002Fgirl, 1yo and older.\n* Subject suffering from drowning related-Acute Respiratory Failure (whatever the nature of water, salt or fresh) and benefiting from the Emergency Medical Service intervention;\n* Acute Respiratory Failure defined as the presence of:\n\n  * Capillary O2 saturation \\\u003C92% upon Emergency Medical Service first clinical analysis at the drowning scene;\n  * Need for oxygen supply 15Liters\u002Fminutes to reach capillary O2 saturation ≥ 95%;\n  * Combination of Acute Respiratory Failure clinical signs: at least 1 of the following items: respiratory rate \\>30\u002Fmin, sternal or clavicular indrawing, abdominal breathing, cyanosis.\n* Individual affiliated to or beneficiary of a French health insurance system;\n* Individual with the ability to benefit from the two strategies (ambivalence clause);\n* Adult Individual having signed written informed consent or child subject with an authorization of the parents.\n\nExclusion Criteria:\n\n* Individual with hypothermia ≤ 34°C ;\n* Individual with neurological distress defined by a Glasgow Coma Scale \\\u003C 13 at first clinical assessment and during the first 15 minutes of care ;\n* Individual with hemodynamic distress defined by a systolic blood tension \\\u003C 90 mmHg at first clinical assessment and during the first 15 minutes of care ;\n* Cardiac arrest or respiratory arrest ;\n* Declared pregnancy or breastfeeding ;\n* Patient under legal protection regime for adults.","1 Year",{"count":451,"type":22},210,[25],"The purpose of this study is to assess the Non-Invasive Ventilation-Continuous Positive Airway Pressure efficacy (experimental group) for drowning related Acute Respiratory Failure compared to Oxygen Supply by face mask (15Liters\u002Fminutes) (control group).",[455],"Drowning","2026-02-03",{"date":458,"type":37},"2026-02-06",{"date":460,"type":37},"2024-07-24",{"date":236,"type":22},{"name":43,"class":44},9,{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":23,"phases":473,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":45},"100520838","comparison-of-the-effectiveness-of-an-adapted-physical-activity-program-in-a-dedicated-structure-to-a-self-program-in-patients-in-chronic-phase-of-a-stroke-100520838","NCT06061770","Comparison of the Effectiveness of an Adapted Physical Activity Program in a Dedicated Structure to a Self-program in Patients in Chronic Phase of a Stroke","StrokAPA","Inclusion Criteria:\n\n* Age greater than 18 years\n* Left or right spastic hemiparesis after a first hemorrhagic or ischemic unilateral stroke older than 6 months\n* Walking possible for 6 minutes\n\nExclusion Criteria:\n\n* Inability to walk without human assistance (with or without technical aids)\n* Cognitive impairment that compromises informed consent, including inability to understand the purpose and terms of the protocol\n* Inability to communicate\n* Presence of an additional neurological disorder\n* Medical conditions that contraindicate physical activity, such as an unbalanced cardiovascular or respiratory condition\n* Concurrent participation in another clinical research project",{"count":472,"type":22},40,[25],"This is a prospective, randomized, controlled, two parallel arms, single-blind pilot study. In this design, all included patients in the chronic phase of a stroke will receive both modes of physical activity.\n\nThis study includes patients over 18 years of age with spastic hemiparesis sequelae of a first unilateral hemispheric stroke older than 6 months and able to walk for 6 minutes. The non-inclusion criteria were the inability to walk without human assistance (with or without technical aids), the existence of cognitive disorders compromising informed consent, in particular the inability to understand the objective and the modalities of the protocol, the inability to communicate with the examiners, and the presence of an additional neurological disorder or a pathology contraindicating the practice of physical activity.\n\nThe primary endpoint is based on daily activity measurement by measuring the number of steps per day, collected over the duration of the study, via a Stepwatch™ device. Secondary end points involve a written physical activity report, assessment of walking ability (via walking-test 6, heart rate, and blood pressure), a measure of perceived exertion, stroke-specific quality of life, balance, and motivation to perform physical activity.",[476],"Stroke",{"date":435,"type":37},{"date":479,"type":37},"2024-09-27",{"date":481,"type":22},"2027-03-26",{"name":43,"class":44},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":359,"minAge":53,"maxAge":491,"enrollmentInfo":492,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":45},"100505132","phase-2-safety-and-potential-effect-of-innovative-treatment-by-adjuvant-injection-of-stromal-vascular-fraction-from-autologous-adipose-tissue-of-urethral-stenosis-with-endoscopic-urethrotomy-100505132","NCT05857371","Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy","Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy: Randomized Controlled Trial","SURF","Inclusion Criteria:\n\n* Signed informed consent\n* Male, aged from 18 to 85 years\n* Bulbar urethral stenosis ≤ 3 cm.\n* At least one urethral dilatation or urethrotomy for the bulbar stenosis in the past 24 months before diagnosis of stenosis\n* Ability to avoid corticoids or immunosuppressive drugs one month after treatment. For any patients with either corticoid or immunosuppressive treatment the physician in charge of this treatment will be contacted and asked to give a written approval for one month cessation of the therapy\n* Good general health status according to clinical history and a physical examination\n* BMI \\> 18 to insure adequate access to abdominal or other subcutaneous adipose tissue for adipose tissue harvesting\n\nExclusion Criteria:\n\n* Urethral stenosis of other location than bulbar\n* Urethral stenosis length \\> 3 cm\n* Urethral stenosis on reconstructed penis (transgender, post amputation)\n* Prior perineal or pelvic radiotherapy\n* Concurrent urinary tract infection without treatment\n* Concurrent perineal infection\n* Penile cancer \\\u003C 5 years\n* Current or recent history of abnormal, severe, progressive, uncontrolled infectious, hepatic, haematological, gastrointestinal (except CD), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral disease\n* Congenital or acquired immunodeficiencies\n* Contraindication to the anaesthetic or surgical procedure\n* Corticoids or immunosuppressive drugs \\> 3 months\n* Any active viral infection among the following: HIV, HTLV I and II, VHB, VHC and syphillis\n* Administrative restricted rights\n* Presence of signs of obstructive voiding symptoms not directly attributable to the stricture at the discretion of the physician\n* Diagnosis of untreated and unresolved BPH benign prostatic hyperplasia or BNC bladder neck contracture\n* Diagnosis of carcinoma of the urethra, bladder or prostate within the last two (2) years","85 Years",{"count":219,"type":22},[57],"SURF is a randomised controlled, parallel group, single blind phase II study designed to assess the safety and potential efficacy of an innovative therapeutic strategy for urethral stenosis based on adjuvant injection of autologous Adipose-Derived Stromal Vascular Fraction of Adipose Tissue (ADSVF) during endoscopic urethrotomy (standard care).",[496],"Urethral Stenosis",{"date":498,"type":37},"2026-02-04",{"date":500,"type":37},"2024-03-13",{"date":502,"type":22},"2028-04",{"name":43,"class":44},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":18,"minAge":388,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":23,"phases":514,"briefSummary":515,"conditions":516,"keywords":518,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":45},"100486873","deployment-of-teleconsulting-in-geriatric-oncology-for-older-patients-100486873","NCT05619731","Deployment of Teleconsulting in Geriatric Oncology for Older Patients","Deployment of Teleconsulting in Geriatric Oncology for Patients Aged 75years or Older Initiating an Oncologic Treatment and Living in Remote Area With no or Few Access to Geriatric Oncology Evaluation Nearby Their Oncologic Treatment Center","TeleOncoGe","Inclusion Criteria:\n\n* Patients 75 years and older\n* Suffering from all types and all stages of cancer and treated for cancer in participating centers\n* G8 (screening tool) ≤ 14\u002F17\n* Agreeing to benefit from a geriatric oncology assessment\n* Having signed a consent\n* Affiliated to French social security or a similar French solidarity scheme\n\nExclusion Criteria:\n\n* Patients under guardianship or curatorship or inability to sign consent\n* Patients with severe cognitive impairment (MMSE \\\u003C 10\u002F30)\n* Patients with severe hearing or visual impairments as these patients will have difficulty performing the telemedicine consultation\n* Patients with a significant language barrier without an interpreter present because these patients will have difficulty carrying out the Telemedicine consultation\n* Patients with expectancy less than 3 months",{"count":513,"type":22},500,[25],"Cancer affects mostly older adults. The development of Geriatric Oncology has greatly improved the management of older patients with the Comprehensive Geriatric Assessments (CGA) being conducted before cancer treatment. A CGA encompasses several dimensions such as comorbidities, but also functional, nutritional or cognitive domains. The International guidelines recommended establishing cooperation with pharmacists as part of the CGA in order to review prescriptions of older patients with cancer and to avoid adverse side effects of treatment. However, the CGA before starting oncological treatment offer is limited in France, especially in some regions which are less populated, or where access to medical centers are difficult. The main objective of our work is to evaluate the impact of telemedicine in geriatric oncology consultation of unexplained re-hospitalization rate at 3 months in the acute care unit. The secondary objectives are to evaluate the impact of telemedicine on unexplained re-hospitalization rate at 6 months, on the secondary toxicities, on the postoperative complications in patients treated surgically, on the overall survival and on the acceptance of the pharmaceutical recommendations by the physicians, but also the impact of telemedicine in medico-economic terms and the satisfaction of patients and oncologists benefiting from teleconsultation.\n\nIt is a multicenter, prospective, randomized study involving 500 patients in 9 participating centers, including 6 peripheral hospitals. The experiment will be represented by the implementation of telemedicine in oncology centers where this expertise is not very available, allowing them to benefit from geriatric oncology teleconsultation and pharmaceutical tele-expertise carried out by three university hospitals. Patients recruited by oncologists, according to the inclusion criteria, will give their written consent to participate. Centers were randomized. In the control arm, patients will be treated according to the usual oncological management as defined for each type of cancer. In the interventional arm, patients will benefit from a CGA with a geriatric oncology teleconsultation as well as a pharmaceutical tele-expertise before the initiation of oncological treatment.",[517],"Cancer",[519,520,517,521,522,523],"Older adults","Telemedecine","Pharmaceutical expertise","Comprehensive Geriatric Assessment","Unexplained re-hospitalization",{"date":498,"type":37},{"date":526,"type":37},"2023-10-18",{"date":528,"type":22},"2027-05-18",{"name":43,"class":44},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":539,"briefSummary":541,"conditions":542,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":545,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":45},"100483183","phase-4-linezolid-or-vancomycin-surgical-site-infection-prophylaxis-100483183","NCT05571722","Linezolid or Vancomycin Surgical Site Infection Prophylaxis","LOVip","Inclusion Criteria:\n\n* Patients undergoing any elective surgery for which vancomycin is recommended in the guidelines as an alternative to beta-lactams including: neurosurgery, cardiac surgery, orthopedic surgery, vascular surgery, penile and testicular surgery, gastric banding procedure in digestive surgery.\n\nThis inclusion criteria can lead to the inclusion of patients who undergo a re-intervention provided that the re-intervention is not due to a suspected or proven infection and that the patient was not included in LOVip at the time of his\u002Fher first intervention;\n\n* Age ≥ 18 years-old;\n* Known allergy to beta-lactams AND\u002FOR suspected or proven MRSA colonization. Proven MRSA colonization is defined as a positive patient sample (any type of swab or biological fluid) for MRSA within 3 months prior to surgery. MRSA colonization is suspected when the patient undergoing surgery has received antibiotic treatment within 3 months prior to surgery or is undergoing re-intervention more than 5 days after the first surgery. MRSA is defined as a strain of Staphylococcus aureus resistant to oxacillin or cefoxitin, predicting non-susceptibility to all classes of beta-lactam antimicrobials (except anti-MRSA cephalosporins) (6). In contrast, MSSA is defined as an oxacillin sensitive strain of Staphylococcus aureus;\n* Informed consent of the patient;\n* Affiliated to a social security system or equivalent.\n\nExclusion Criteria:\n\n* Surgery for suspected or proven SSI (definition of SSI provided on chapter 3.6.1 Primary endpoint as defined by (5, 7)) according to international definitions;\n* Obesity defined by a body mass index (BMI) \\> 35 kg\u002Fm2 or a body weight \\> 100 kg;\n* Chronic kidney disease defined as glomerular filtration rate (GFR) \\\u003C 60 ml\u002Fmin per 1.73m2;\n* Known allergy to linezolid or vancomycin;\n* Hematologic malignancy;\n* Declared pregnancy or breastfeeding;\n* Patient under legal protection regime for adults;\n* Patient denying consent;\n* Patient already included in LOVip for a previous surgery.",{"count":538,"type":22},1160,[540],"PHASE4","Anesthesia and surgical guidelines recommend the administration of a surgical antibiotic prophylaxis for patients undergoing \"clean\" surgery. The prescribed antibiotic should target the bacteria most commonly found in surgical site infections (SSIs) and the duration of administration should not exceed 24 hours to minimize the ecological risk of bacterial resistance emergence. Guidelines provide a framework for the administration of surgical antibiotic prophylaxis but their effectiveness is regularly re-evaluated by measuring the rates of SSIs and the microorganisms responsible for infectious complications after surgery.\n\nThe majority of interventions required the use of first or second generation cephalosporins as surgical antibiotic prophylaxis. For patients with allergy to beta-lactams, clindamycin and vancomycin are proposed as alternatives. In the patients with methicillin-resistant S. aureus (MRSA) colonization or if those at risk of developing MRSA-associated SSI (hospital ecology, previous antibiotic treatment), only vancomycin is recommended. Vancomycin pharmacokinetics and pharmacodynamics is complex and its tissue absorption varies according to the level of tissue inflammation. This is a difficult molecule to handle, exclusively administered via intravenous route.\n\nLinezolid is a synthetic antibiotic from the oxazolidinone class. By binding to the rRNA on the 30S and 50S ribosomal subunits, it inhibits the bacterial synthesis. It is therefore a bacteriostatic antibiotic approved for the treatment of both methicillin susceptible S. aureus (MSSA) and MRSA infections. It also covers a broad spectrum of Gram positive bacteria. Its pharmacokinetics allows rapid intravenous infusion, with rapid penetration into bone and soft tissue of the surgical site during hip surgery. A large Cochrane meta-analysis reported that linezolid was superior to vancomycin in skin infections, including MRSA infections, albeit with low quality evidence.\n\nWe therefore hypothesized that linezolid can be used instead of vancomycin for beta-lactam allergic patients and patients at risk of MRSA-associated SSI in general surgery.",[543,544],"Antibiotic Prophylaxis","General Surgery",{"date":435,"type":37},{"date":547,"type":37},"2024-11-12",{"date":549,"type":22},"2029-12-03",{"name":43,"class":44},{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":192,"phases":4,"briefSummary":561,"conditions":562,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":564,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":45},"100504975","association-between-the-level-of-ev-tf-and-the-occurence-of-pulmonary-embolism-in-patients-with-ards-100504975","NCT05855317","Association Between the Level of EV-TF and the Occurence of Pulmonary Embolism in Patients With ARDS","Association Between the Level of Extracellular Vesicle - Associated Tissue Factor and the Occurence of Pulmonary Embolism in Patients With Acute Respiratory Distress Syndrome","THROMBO-EVTF","Inclusion Criteria:\n\n* Patient 18 years of age or older,\n* Patient who has given his\u002Fher non-opposition to participate in this study, or alternatively, patient for whom a relative has given his\u002Fher non-opposition to participate in this study,\n* Patient admitted to intensive care for less than 24 hours,\n* Patient with ARDS according to the Berlin criteria,\n\n  * Hypoxemia with PaO2\u002FFiO2 ratio ≤ 300 on mechanical ventilation under PEEP ≥ 5 cmH2O,\n  * Bilateral alveolar-interstitial opacities on chest imaging (chest X-ray or CT),\n  * Exclusion of a cardiogenic cause on echocardiography,\n  * Acute or subacute onset within 7 days based on the clinical-radiological profile.\n\nExclusion Criteria:\n\n* Positive SARS-CoV-2 PCR in a pharyngeal or respiratory sample (cytobacteriological examination of sputum, bronchial aspiration or bronchoalveolar lavage) prior to admission to the intensive care unit,\n* Patient with a pathology affecting the coagulation process or endothelial function (hemophilia, von Willebrand disease, etc.),\n* Patient receiving curative anticoagulant treatment before admission to the intensive care unit,\n* Patient undergoing extracorporeal veno-venous respiratory assistance (ECMO-VV) before admission to the intensive care unit,\n* Patient undergoing extra-renal purification with systemic anticoagulation with heparin before admission to the intensive care unit,\n* Persons referred to in articles L. 1121-5 to L. 1121-8 of the Public Health Code (minor patients, adult patients under tutorship or guardianship, patients deprived of their liberty, pregnant or nursing women),\n* Moribund patients for whom the life expectancy is less than 24 hours according to the opinion of the investigating physician.",{"count":560,"type":22},170,"In this study, 120 patients with Acute Respiratory Distress Syndrome (ARDS) will be included on a two years-period in an intensive care unit (Assistance Publique des Hôpitaux de Marseille, France). Those patients will benefit from a blood test at inclusion in order to measure several coagulation biomarkers, including EV-TF. Subsequently, these patients will be treated according to the usual practices of the department, following recommendations. Patients who received an injected CT scan between Day 5 and Day 28 will be divided into two groups based on the presence or absence of a pulmonary embolism on imaging. The measured values of EV-TF levels and other studied biomarkers will be compared between these two groups in order to detect a possible association between them and the diagnosis of pulmonary embolism. It should be noted that patients receiving an injected CT-scan between Day 5 and Day 7 will be included in the main analysis while those receiving it between Day 8 and Day 28 will be included in the secondary analysis. Others will be excluded from any analysis. At the same time, several collections of clinical data will be carried out: on Day 1, Day 7, Day 28, and on the day of the CT scan if it is performed at another time.",[563],"Acute Respiratory Distress Syndrome",{"date":498,"type":37},{"date":566,"type":37},"2023-10-31",{"date":568,"type":22},"2027-10-30",{"name":43,"class":44},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":577,"targetDuration":4,"studyType":23,"phases":578,"briefSummary":579,"conditions":580,"keywords":583,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":4},"100621874","use-of-anti-cd146-autoantibodies-for-the-diagnosis-of-pulmonary-diseases-secondary-to-occupational-exposure-to-silica-100621874","NCT07376291","Use of Anti-CD146 Autoantibodies for the Diagnosis of Pulmonary Diseases Secondary to Occupational Exposure to Silica","CD146-SILICE","Inclusion Criteria for non-exposed group:\n\n* Subject, male or female, aged 18 or over\n* Subject with low exposure to silica \\\u003C0.1 mg\u002Fm3 in the course of their professional activity, quantified during an occupational health consultation using an employment-exposure matrix\n* Subjects capable of consenting to participate in the study by signing a written informed consent form\n* Subjects who are beneficiaries of or affiliated with a social security system\n\nInclusion Criteria for exposed group:\n\n* Subject, male or female, aged 18 or over\n* Subject with moderate or high exposure to silica (\\>= 0.1 mg\u002Fm3) in the course of their professional activity, quantified during an occupational health consultation using an employment-exposure matrix.\n* Subjects capable of consenting to participate in the study by signing a written informed consent form\n* Subjects who are beneficiaries of or affiliated with a social security system\n\nExclusion Criteria for each group:\n\n* Minor subject\n* Subject refusing to undergo the examinations required by the protocol\n* Contraindications to respiratory function tests: Recent eye or throat surgery, recent myocardial infarction or pulmonary embolism, poorly controlled high blood pressure, recent pneumothorax.\n* Pregnant or breastfeeding women, patients under guardianship or curatorship, deprived of liberty",{"count":410,"type":22},[25],"This prospective, multicenter study aims to evaluate the relevance of anti-CD146 autoantibodies (AACD146) as biological markers for the early diagnosis of pulmonary diseases related to occupational exposure to silica. Silica exposure is a recognized risk factor for fibrotic, inflammatory, and cancerous respiratory diseases. Currently, no specific biological marker exists. The hypothesis is that AACD146 reflects early effects of silica exposure. The study will include 110 participants divided into two groups (exposed vs. non-exposed) and will compare AACD146 prevalence according to exposure level and the presence of respiratory diseases.",[581,582],"Exposure Occupational","Pulmonary Diseases",[584,585,586],"silica","Exposure occupational","Pulmonary diseases","2026-01-29",{"date":278,"type":37},{"date":590,"type":22},"2026-06",{"date":592,"type":22},"2028-06",{"name":43,"class":44},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":23,"phases":603,"briefSummary":604,"conditions":605,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":45},"100326191","prospective-cohort-of-patients-with-newly-diagnosed-glioblastoma-analysis-of-mmp2-and-mmp9-expression-and-correlation-to-neuro-imaging-features-100326191","NCT03526822","Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.","MM-Predict","Inclusion Criteria:\n\n* Patient, male or female, aged 18 years or over\n* Imaging suggestive of glioblastoma\n* Patient eligible for excision surgery (partial, subtotal or macroscopically complete)\n* Candidate for concomitant and adjuvant radiotherapy chemotherapy (Stupp protocol)\n* Patient having signed an informed consent\n* Patient having undergone a preoperative MRI\n\nExclusion Criteria:\n\n* Existence of a contraindication to the MRI\n* Nonoperable lesion\n* History of radiotherapy and \u002F or chemotherapy for this lesion\n* Scalability of a low grade lesion\n* Person in emergency situation, a legal person of legal age (guardianship, guardianship or legal guardianship), or unable to express his or her consent\n* No affiliation to a social security scheme (beneficiary or beneficiary)\n* Pregnant or lactating woman",{"count":602,"type":22},100,[25],"Glioblastoma is the most frequent and aggressive primary brain tumor in adults. A team recently showed that baseline plasma levels of matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) were correlated to bevacizumab activity in patients with recurrent glioblastoma. To date, the biological rationale of this results remains unknown but MMP2 could be involved in classical angiogenesis while MMP9 could promote vasculogenesis.\n\nThe objectives are to correlate the plasma levels of MMP2 and MMP9 to their Ribonucleic acid (RNA) and protein tissue expression, activity and to patient neuro-imaging features. To analyze the changes of MMP2 and MMP9 plasma levels during peri-operative period and after radio-chemotherapy.\n\nMethods: Plasmatic levels of MMP2, MMP9, vascular endothelial growth factor-A (VEGFA), vascular endothelial growth factor-R2 (VEGFR2), stromal cell-derived factor 1 (SDF1) and chemokine receptor-4 (CXCR4) will be analyzed by enzyme-linked immunosorbent assay (ELISA) in pre-, post-operative period, before radiotherapy, before adjuvant temozolomide and at relapse in newly diagnosed glioblastoma. RNA expression of these factors will be analyzed by reverse transcription-Polymerase chain reaction (RT-qPCR) on frozen tumor samples, whereas protein expression will be analyzed by ELISA and immunohistochemistry. Enzymatic activity of MMP2 and MMP9 will be analyzed by zymography. Tumor volume, infiltration and perfusion degrees will be analyzed on Magnetic Resonance Imaging (MRI) performed before and after surgery and before adjuvant temozolomide. Neuro-imaging characteristics will be correlated to plasma and tissue expressions of these factors.\n\nThe expected results are to better define the expression profile of MMP2, MMP9 and the change in their plasma level during treatment, a prerequisite for their clinical use.",[606],"Brain Tumor","2026-01-26",{"date":609,"type":37},"2026-01-28",{"date":611,"type":37},"2018-07-02",{"date":613,"type":22},"2028-01-01",{"name":43,"class":44},""]